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Successful control of feline and equine skin 
neoplasia by Viscum album extracts (ISCADOR) 
considering special issues in human medicine
Introduction
Extracts of European Mistletoe (viscum 
album sp.) such as Iscador® are applied to 
cancer patients as primary or complemen-
tary therapy for more than 80 years. Several 
investigations has been showing a positive 
outcome for human patients. In horses 
semi-malignant Equine Sarcoid (ES) is a rel-
evant problem due to it’s tendency to recur 
after surgery and it’s amount of tumor num-
bers per horse. Feline Fibrosarcoma (FFS) 
is very common in cat populations and is 
associated to vaccination, hypothetically to 
injections in general. Therefore, results of 
two different clinical research projects under 
practical conditions in horses and cats are 
presented.
Animals, Material & Methods
Tumor disease Study I: Equine Sarcoid (ES) Study II Feline Fibrosarcoma (FFS)
Species Horses (n=53) Cats (n=44)
Therapy strategy Monotherapy & Monotherapy + 
selective surgery
Recurrence prophylaxis after 
excision
Formulation Iscador P Ser. I (0.1-10mg/ml), 
II (1-20mg/ml) & 20mg
Viscum quercus dil. Aqu. 1mg/ml 
(Weleda)
Protocol Series I (14 inj.), Series II 
(14 inj.), 20 mg/ml (15 inj.) 
Twice daily 10 drops each
Administration s.c. Peroral (to avoid injections)
Length 15 weeks Permanently until break by owner 
or death
Primary outcome cure rate, improvement rate (tu-
mour size/count reduction >50%)
disease free survival time
Study design prospective placebo controlled 
blind study
prospective drug monitoring study
Statistics Chisquare test for outcome com-
parison (STATA)
Kaplan-Meier Survival stimulation 
(CRAN R)
Results
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Figure 1: Cure and improvement rates on horse level 3 to 12 month after treatment
start. Improvement rates with different index a,b are significantly different (p<0.05)
a
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Figure 2: Kaplan-Meier Survival Function of study population (n=44 cats) and
comparison of median Disease Free Survival Time (DFST) to literature data
Discussion and Conclusions
Equine sarcoids respond to therapy with subcutanously ap-
plied ISCADOR P with significant higher improvement rates 
compared to placebo. There is no significant difference be-
tween groups after 15 weeks of therapy. Highest therapy 
effects occur one year after treatment indicating a pro-
longed effect by ISCADOR beyond therapy course. 
Orally administered viscum extracts after tumor excision 
show similar results (median DFST 421 days) as additional 
chemo-therapy in FFS, but nearly without undesired side 
effects. Only aggressive therapy protocols are able to ex-
tend disease free survival time.
ISCADOR® is a valuable therapy approach for neoplasia in 
animals. The presented protocols raise the discussion about 
oral therapy and frequency of therapy courses in human 
patients, too.
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